Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

Kaidi Wang,Jian Ji,Junmei Zhao,Qing Liu,Ke Yao,Zhilan Yuan,Aiwu Fang,Liang Xu,Xinghuai Sun,Li Xu,Lingling Wu,Jiamin Hou,Mingzhi Zhang

doi:10.1186/1471-2415-14-21

Abstract

BackgroundTo report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.MethodsTwo hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.ResultsAmong 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 ± 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 ± 2.8 mmHg (9.5%) to 6.4 ± 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.ConclusionsOur results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.

Highlights

To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy
Conclusive evidence from many well-conducted clinical trials have shown that intraocular pressure (IOP) reduction is beneficial to control the glaucomatous damage for either glaucoma or ocular hypertension patients [3,4,5,6,7]
Study population and patient demographics A total of 263 eligible patients were enrolled in the study for bimatoprost therapy

Summary

Introduction

To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy. The prostaglandin/prostamide (PG/PM) class of medications has been shown to be highly effective in IOP lowering with favorable tolerance and are used as the first-line ocular antihypertensive agents for glaucoma treatment in many countries [8]. Among these medications, the PM bimatoprost represents a pharmacologically distinct drug that has been approved on the United States market since 2001 for glaucoma and ocular hypertension (OHT) treatment. But not yet in China, a new 0.01% formulation of bimatoprost is available; bimatoprost 0.01% has been demonstrated to have efficacy equivalent to the original bimatoprost 0.03% formulation and be associated with less frequent and less severe conjunctival hyperemia [21]

Methods

Results

Discussion

Conclusion